In vitro activities of a new des-fluoro(6) quinolone, garenoxacin, against clinical anaerobic bacteria

被引：31

作者：

Liebetrau, A

Rodloff, AC

Behra-Miellet, J

Dubreuil, L

机构：

[1] Univ Leipzig, Inst Med Microbiol & Epidemiol Infect Dis, D-04103 Leipzig, Germany

[2] Univ Lille, Fac Pharm, Head Dept Microbiol, Lille, France

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2003年 / 47卷 / 11期

关键词：

D O I：

10.1128/AAC.47.11.3667-3671.2003

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The antimicrobial activities of garenoxacin and eight other antibiotics against 641 anaerobic isolates were evaluated with the NCCLS agar dilution method. Overall, the MICs of garenoxacin for 50 and 90% of the strains tested (in micrograms per milliliter) were as follows: Bacteroides fragilis group, 0.5 and 2; Prevotella spp., 0.25 and 2; Fusobacterium spp., 0.25 and 0.5; Porphyromonas spp., 0.125 and 0.25; Bilophila wadsworthia, 0.5 and 1; Veillonella spp., 0.25 and 0.5; Clostridium spp., 0.25 and 1; Clostridium difficile, 2 and >64; Bifidobacterium spp., 1 and 2; Eggerthella lenta, 0.25 and 1; Propionibacterium spp., 0.5 and 0.5; gram-positive cocci, 0.125 and 0.25.

引用

收藏

页码：3667 / 3671

页数：5

相关论文

共 31 条

[1]

ACAR J, 1998, PATHOL BIOL, V46, P1

[2] Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA [J].

Ackermann, G ;

Tang, YJ ;

Kueper, R ;

Heisig, P ;

Rodloff, AC ;

Silva, J ;

Cohen, SH .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (08) :2348-2353

[3] Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria [J].

Ackermann, G ;

Schaumann, R ;

Pless, B ;

Claros, MC ;

Goldstein, EJC ;

Rodloff, AC .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2000, 19 (03) :228-232

[4]

Ackermann G, 2001, J ANTIMICROB CHEMOTH, V47, P722

[5] Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species [J].

Aldridge, KE ;

Ashcraft, D ;

Cambre, K ;

Pierson, CL ;

Jenkins, SG ;

Rosenblatt, JE .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (04) :1238-1243

[6] Antimicrobial activities of BMS-284756 compared with those of fluoroquinolones and β-lactams against gram-positive clinical isolates [J].

Bassetti, M ;

Dembry, LM ;

Farrel, PA ;

Callan, DA ;

Andriole, VT .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (01) :234-238

[7] Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin [J].

Bauernfeind, A .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (05) :639-651

[8] COMPARATIVE INVITRO ACTIVITIES OF THE NEW QUINOLONE, BAY-Y-3118, AND CIPROFLOXACIN, SPARFLOXACIN, TOSUFLOXACIN, CI-960 AND CI-990 [J].

BAUERNFEIND, A .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 31 (04) :505-522

[9] Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group:: Comparison with the activities of 14 other agents [J].

Betriu, C ;

Gómez, M ;

Palau, ML ;

Sánchez, A ;

Picazo, JJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (09) :2320-2322

[10] SURVEY OF THE SUSCEPTIBILITY PATTERNS OF BACTEROIDES-FRAGILIS GROUP STRAINS IN FRANCE FROM 1977 TO 1992 [J].

DUBREUIL, L ;

BREUIL, J ;

DUBLANCHET, A ;

SEDALLIAN, A .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1992, 11 (11) :1094-1099

← 1 2 3 4 →